Keryx Biopharmaceuticals (KERX) Announces Zerenex™ (Ferric Citrate Coordination Complex) Phase 2 Results In Non-Dialysis Dependent Chronic Kidney Disease Selected As A Late Breaking Oral Presentation At The Upcoming National Kidney Foundation 2014 Spring Clinical Meeting
4/9/2014 7:59:05 AM
NEW YORK, April 9, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced that Phase 2 clinical results of Zerenex™ (ferric citrate coordination complex) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26, 2014 in Las Vegas, NV. This presentation, entitled "Zerenex™ (Ferric Citrate) for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late Breaking Session on Friday, April 25, 2014, from 9:30am - 11:00am PDT, by Dr. Geoffrey Block, Director of Clinical Research at Denver Nephrology and Co-Chairman for this study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by